rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Sunshine Biopharma Inc.

SBFM · Nasdaq

Health CareBiotechnologyNot moving yet

SBFM stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 94.6% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
1
Institutions holding
9 (-3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

1 disclosed lines: House 1, Senate 0, executive 0; 1 people.

WhoDidAmountTraded
Roger Williams House: U.S. House ClerkTX25boughtspouse$1k–$15k30 Jun 2022filed 12 Jun 2024

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders9-3 on the quarter
New · exited3 · 6
Reported value$33K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
JANE STREET GROUP, LLCnew · filed 14 Aug 202614,974$31K+14,974
MORGAN STANLEYreduced · filed 13 Aug 2026385$808-14,249−97.4%
SBI Securities Co., Ltd.reduced · filed 23 Jul 2026162$340-1,672−91.2%
NATIONAL BANK OF CANADAreduced · filed 10 Aug 20265$10-4−44.4%
OSAIC HOLDINGS, INC.unchanged · filed 14 Aug 20262$400.0%
Caitong International Asset Management Co., Ltdnew · filed 5 Aug 20261$2+1
Farther Finance Advisors, LLCunchanged · filed 17 Jul 20261$200.0%
TD Waterhouse Canada Inc.unchanged · filed 27 Jul 20261$200.0%
Strive Financial Group ,LLCnew · filed 4 Aug 20261$2+1
31 Mar 2023 – 30 Jun 2026
81114Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

David Natan Company insiderDirector · last 7 Aug 20260 · 0
Steve N. Slilaty Company insiderChief Executive Officer · last 4 Mar 20244 · 1
Camille Sebaaly Company insiderCFO/Secretary · last 30 Nov 20222 · 0
Roger Williams HouseTX25 · last 30 Jun 20221 · 0
Abderrazzak Merzouki Company insiderChief Operating Officer · last 6 Jan 20210 · 0
Advanomics Corp Company insider10% owner · last 10 Oct 20160 · 0

Same industry

MRNA ModernaLeading+147%
IOVA Iovance BiotherapeuticsLeading+126%
ABCL AbCellera BiologicsLeading+60%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+38%
ENTX Entera BioLeading+37%
HELP Helus PharmaLeading+36%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202533.8%
Operating profit marginFY 2025 · to 31 Dec 2025-17.2%
Free cash flow marginFY 2025 · to 31 Dec 2025-15.2%
Return on capital employedFY 2025 · to 31 Dec 2025-26.3%
Research spendFY 2025 · to 31 Dec 20251.7%
Share count trendFY 2025 · to 2 Apr 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$9.1M
Free cash flowFY 2025 · to 31 Dec 2025−$5.5M

Analyst forecasts

No analyst forecasts yet.